Literature DB >> 14759363

The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.

James Griffith1, James Black, Carlos Faerman, Lora Swenson, Michael Wynn, Fan Lu, Judith Lippke, Kumkum Saxena.   

Abstract

FLT3 is a type III receptor tyrosine kinase that is thought to play a key role in hematopoiesis. Certain classes of FLT3 mutations cause constitutively activated forms of the receptor that are found in significant numbers of patients with acute myelogenous leukemia (AML). The mutations occur either in the activation loop, for example, as point mutations of Asp835 or as internal tandem duplication (ITD) sequences in the juxtamembrane (JM) domain. To further understand the nature of FLT3 autoinhibition and regulation, we have determined the crystal structure of the autoinhibited form of FLT3. This structure shows the autoinhibitory conformation of a complete JM domain in this class of receptor tyrosine kinases. The detailed inhibitory mechanism of the JM domain is revealed, which is likely utilized by other members of type III receptor tyrosine kinases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14759363     DOI: 10.1016/s1097-2765(03)00505-7

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  150 in total

1.  Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.

Authors:  Jennifer L Rocnik; Rachel Okabe; Jin-Chen Yu; Benjamin H Lee; Neill Giese; David P Schenkein; D Gary Gilliland
Journal:  Blood       Date:  2006-04-20       Impact factor: 22.113

Review 2.  Receptor tyrosine kinase transmembrane domains: Function, dimer structure and dimerization energetics.

Authors:  Edwin Li; Kalina Hristova
Journal:  Cell Adh Migr       Date:  2010-04-23       Impact factor: 3.405

Review 3.  FLT3 inhibitors in AML: are we there yet?

Authors:  Akshay Sudhindra; Catherine Choy Smith
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

Review 4.  Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.

Authors:  Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

Review 5.  FLT3 antibody-based therapeutics for leukemia therapy.

Authors:  Yiwen Li; Zhenping Zhu
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

Review 6.  Impact of the Protein Data Bank on antineoplastic approvals.

Authors:  John D Westbrook; Rose Soskind; Brian P Hudson; Stephen K Burley
Journal:  Drug Discov Today       Date:  2020-02-14       Impact factor: 7.851

7.  SYK is a critical regulator of FLT3 in acute myeloid leukemia.

Authors:  Alexandre Puissant; Nina Fenouille; Gabriela Alexe; Yana Pikman; Christopher F Bassil; Swapnil Mehta; Jinyan Du; Julhash U Kazi; Frédéric Luciano; Lars Rönnstrand; Andrew L Kung; Jon C Aster; Ilene Galinsky; Richard M Stone; Daniel J DeAngelo; Michael T Hemann; Kimberly Stegmaier
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

8.  Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors.

Authors:  Brendan Frett; Nick McConnell; Catherine C Smith; Yuanxiang Wang; Neil P Shah; Hong-yu Li
Journal:  Eur J Med Chem       Date:  2015-02-28       Impact factor: 6.514

Review 9.  Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Authors:  Keith Pratz; Mark Levis
Journal:  Leuk Lymphoma       Date:  2008-05

10.  FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells.

Authors:  Kentaro Fukushima; Itaru Matsumura; Sachiko Ezoe; Masahiro Tokunaga; Masato Yasumi; Yusuke Satoh; Hirohiko Shibayama; Hirokazu Tanaka; Atsushi Iwama; Yuzuru Kanakura
Journal:  J Biol Chem       Date:  2009-01-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.